The World Anti-Doping Agency (WADA) announced yesterday that its Executive Committee approved the Prohibited List of Substances and Methods for 2005. The new List will be published prior to October 1, 2004, and will go into effect January 1, 2005.
Some changes will be made from the current List in 2005. For example, the topical application of glucocorticosteroids will no longer require an abbreviated therapeutic use exemption. Beta-2 agonists, often used in the treatment of asthma, will now be prohibited both in and out of competition. Due to the findings of a WADA-sponsored research project, Finasteride, a product used for prostate problems in men and also for hair loss, will be added to the Prohibited List as a masking agent. Finally, intravenous infusion for non-medical purposes will now be explicitly banned.
The Executive Committee based its decisions regarding the List on the recommendations of WADA's List Committee and Health-Medical and Research Committee, which met in September to discuss the 2005 List. Since 2004, WADA has been tasked with issuing the List on an annual basis, a responsibility previously held by the International Olympic Committee (IOC). A substance or method is added to the List if it meets two of three criteria: it is performance enhancing, poses a danger to athletes' health, and its use is against the spirit of sport.
"Refining the List is an important part of WADA's responsibilities under the World Anti-Doping Code,"
said Richard W. Pound, WADA's president. "The changes we have made this year reflect our expanding scientific knowledge and our ability to better identify performance enhancing substances and methods."
The 2005 Prohibited list is effective in sport from 1 January 2005 and a copy will be published prior to that date on the ISAF Medical microsite by following the link below.
For the full story on the WADA Executive Committee Meetings, please follow the link to the WADA website at the address below.